

Erelzi ^[1]

PRErelzi™

Erelzi™ (etanercept) is a biosimilar to the Canadian authorized reference product, Enbrel®. Erelzi™ is indicated for use in Rheumatoid Arthritis, Ankylosing Spondylitis and Juvenile Idiopathic Arthritis.

Erelzi™ is the second Sandoz biosimilar available in Canada.

Click [here](#) ^[2] to consult the monograph of Erelzi™

* Erelzi™ is trademark owned or used under license by Sandoz Canada Inc.

** Enbrel® is a registered trademark of Amgen in Canada.

*** Sandoz Canada has not sought the approval of Erelzi™ for the treatment of psoriatic arthritis or plaque psoriasis at this time.

Publish Date:

Jul 26, 2017

Accordion Type:

Collapsible

Source URL: <https://www.sandoz.ca/en/produits/patients/biopharmaceutique/erelzi>

Links

[1] <https://www.sandoz.ca/en/produits/patients/biopharmaceutique/erelzi>

[2] <https://prod.sandoz.ca/sites/www.sandoz.ca/files/Erelzi-Product-Monograph.pdf>